Home › Companies › BIOCRYST PHARMACEUTICALS INC. › 2024-2025
Compiled from SEC Form N-PX filings and BIOCRYST PHARMACEUTICALS INC.’s Form 8-K, filed June 16, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 12, 2025: 5 items on BIOCRYST PHARMACEUTICALS INC.’s Form 8-K, filed June 16, 2025: 2 elected · 3 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore BIOCRYST PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are BIOCRYST PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Steven K. Galson, M.D., MPH | 146,067,707 | -- | -- | 3,688,084 | -- | 98% | Elected | — |
| Elect Director: Alan G. Levin | 146,065,836 | -- | -- | 3,689,955 | -- | 98% | Elected | — |
| The proposed ratification of the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2025 was approved by the following votes: | 174,697,892 | 3,838,292 | 492,505 | -- | -- | 98% | Approved | — |
| The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes: | 143,096,094 | 6,357,577 | 302,120 | -- | 29,272,898 | 96% | Approved | — |
| The Incentive Plan Proposal was approved by the following votes: | 110,230,306 | 38,875,495 | 649,990 | -- | 29,272,898 | 74% | Approved | — |
Source: BIOCRYST PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 16, 2025 — read the filing on EDGAR.
Each item below shows how the 264 asset managers that disclosed a BIOCRYST PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Steven Galson, M.D., MPH
BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Steven K. Galson, M.D., MPH”): 146,067,707 for, 3,688,084 withheld, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 21,170,456 | 0 | 0 | 0 | For |
| BlackRock | 11,197,803 | 0 | 0 | 0 | For |
| Fidelity | 5,530,927 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 3,546,540 | 0 | 0 | 0 | For |
| TIAA | 3,538,660 | 0 | 0 | 0 | For |
| State Street | 3,244,138 | 0 | 0 | 0 | For |
| Charles Schwab | 1,949,072 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,456,895 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 1,036,408 | 0 | 0 | 0 | For |
| Invesco | 839,792 | 0 | 0 | 0 | For |
| First Trust | 650,165 | 0 | 0 | 0 | For |
| Equitable | 328,652 | 0 | 0 | 273,370 | Mixed |
| AMG FUNDS | 529,317 | 0 | 0 | 0 | For |
| John Hancock | 464,407 | 0 | 0 | 0 | For |
| Voya | 382,458 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 357,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 356,586 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 353,540 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 309,522 | 0 | 0 | 0 | For |
| Lincoln Financial | 286,448 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 266,386 | 0 | 0 | 0 | For |
| Goldman Sachs | 250,799 | 0 | 0 | 0 | For |
| Federated Hermes | 182,425 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 152,985 | 0 | 0 | 0 | For |
| American Century | 137,097 | 0 | 0 | 0 | For |
Fund voting reports, all 65 managers: 60,159,359 for, 344,719 withheld, 0 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RP Management, LLC | 3,846,154 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 3,846,154 for.
Combines 7 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Alan Levin
BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Alan G. Levin”): 146,065,836 for, 3,689,955 withheld, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 21,170,456 | 0 | 0 | 0 | For |
| BlackRock | 11,197,803 | 0 | 0 | 0 | For |
| Fidelity | 5,530,927 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 3,546,540 | 0 | 0 | 0 | For |
| TIAA | 3,538,660 | 0 | 0 | 0 | For |
| State Street | 3,244,138 | 0 | 0 | 0 | For |
| Charles Schwab | 1,949,072 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,456,895 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 1,036,408 | 0 | 0 | 0 | For |
| Invesco | 839,792 | 0 | 0 | 0 | For |
| First Trust | 650,165 | 0 | 0 | 0 | For |
| Equitable | 328,652 | 0 | 0 | 273,370 | Mixed |
| AMG FUNDS | 529,317 | 0 | 0 | 0 | For |
| John Hancock | 464,407 | 0 | 0 | 0 | For |
| Voya | 382,458 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 356,586 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 353,540 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 309,522 | 0 | 0 | 0 | For |
| Lincoln Financial | 286,448 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 266,386 | 0 | 0 | 0 | For |
| Goldman Sachs | 250,799 | 0 | 0 | 0 | For |
| Federated Hermes | 182,425 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 152,985 | 0 | 0 | 0 | For |
| American Century | 137,097 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 134,105 | 0 | 0 | 0 | For |
Fund voting reports, all 64 managers: 59,802,359 for, 344,719 withheld, 0 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RP Management, LLC | 3,846,154 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 3,846,154 for.
74% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE STOCK INCENTIVE PLAN.
BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“The Incentive Plan Proposal was approved by the following votes:”): 110,230,306 for, 38,875,495 against — passed, per its Form 8-K filed June 16, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Incentive Plan Proposal was approved by the following votes:”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 21,039,956 | 130,500 | 0 | 0 | For |
| BlackRock | 11,197,803 | 0 | 0 | 0 | For |
| Fidelity | 4,825,802 | 705,125 | 0 | 0 | Mixed |
| ACAP Strategic Fund | 3,546,540 | 0 | 0 | 0 | For |
| TIAA | 0 | 3,538,660 | 0 | 0 | Against |
| State Street | 3,240,118 | 4,020 | 0 | 0 | For |
| Charles Schwab | 1,949,072 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,456,895 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 1,036,408 | 0 | 0 | 0 | For |
| Invesco | 0 | 839,792 | 0 | 0 | Against |
| First Trust | 0 | 650,165 | 0 | 0 | Against |
| Equitable | 328,652 | 273,370 | 0 | 0 | Mixed |
| AMG FUNDS | 0 | 529,317 | 0 | 0 | Against |
| John Hancock | 0 | 464,407 | 0 | 0 | Against |
| Voya | 0 | 382,458 | 0 | 0 | Against |
| HUSSMAN INVESTMENT TRUST | 0 | 357,000 | 0 | 0 | Against |
| Exchange Place Advisors Trust | 356,586 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 353,540 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 0 | 309,522 | 0 | 0 | Against |
| Lincoln Financial | 152,503 | 133,945 | 0 | 0 | Mixed |
| CLEARWATER INVESTMENT TRUST | 87,221 | 179,165 | 0 | 0 | Mixed |
| Goldman Sachs | 0 | 250,799 | 0 | 0 | Against |
| Federated Hermes | 182,425 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 152,985 | 0 | 0 | Against |
| American Century | 0 | 137,097 | 0 | 0 | Against |
Fund voting reports, all 64 managers: 50,425,977 for, 10,027,610 against, 50,417 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RP Management, LLC | 3,846,154 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 3,846,154 for.
Combines 9 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: To hold a non-binding, advisory vote regarding executive compensation.
BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:”): 143,096,094 for, 6,357,577 against — passed, per its Form 8-K filed June 16, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of BIOCRYST PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (6 managers, 2,677,282 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 21,170,456 | 0 | 0 | 0 | For |
| BlackRock | 11,197,803 | 0 | 0 | 0 | For |
| Fidelity | 5,530,927 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 3,546,540 | 0 | 0 | 0 | For |
| TIAA | 3,538,660 | 0 | 0 | 0 | For |
| State Street | 3,244,138 | 0 | 0 | 0 | For |
| Charles Schwab | 1,949,072 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,456,895 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 1,036,408 | 0 | 0 | 0 | For |
| Invesco | 0 | 839,792 | 0 | 0 | Against |
| First Trust | 650,165 | 0 | 0 | 0 | For |
| Equitable | 602,022 | 0 | 0 | 0 | For |
| AMG FUNDS | 529,317 | 0 | 0 | 0 | For |
| John Hancock | 464,407 | 0 | 0 | 0 | For |
| Voya | 382,458 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 0 | 357,000 | 0 | 0 | Against |
| Exchange Place Advisors Trust | 356,586 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 353,540 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 309,522 | 0 | 0 | 0 | For |
| Lincoln Financial | 286,448 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 266,386 | 0 | 0 | 0 | For |
| Goldman Sachs | 250,799 | 0 | 0 | 0 | For |
| Federated Hermes | 182,425 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 152,985 | 0 | 0 | 0 | For |
| American Century | 0 | 137,097 | 0 | 0 | Against |
Fund voting reports, all 64 managers: 59,103,549 for, 1,350,038 against, 50,417 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 9,478,735 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 7,568,494 | 0 | 0 | 0 | For |
| State Street | 7,298,373 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 5,634,066 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 4,996,139 | 0 | 0 | 0 | For |
| RP Management, LLC | 3,846,154 | 0 | 0 | 0 | For |
| Nuveen | 3,559,005 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 2,789,086 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 2,690,579 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 50,150 | 0 | 0 | 0 | For |
| JUPITER ASSET MANAGEMENT LTD | 2,345,747 | 0 | 0 | 0 | For |
| Caligan Partners LP | 2,332,709 | 0 | 0 | 0 | For |
| Two Sigma | 2,041,712 | 0 | 0 | 0 | For |
| Charles Schwab | 1,949,615 | 0 | 0 | 0 | For |
| 1919 Investment Counsel, LLC | 1,831,367 | 0 | 0 | 0 | For |
| Northern Trust | 1,657,259 | 0 | 0 | 0 | For |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,580,426 | 0 | 0 | 0 | For |
| DE Shaw | 1,458,450 | 0 | 0 | 0 | For |
| Invesco | 0 | 957,245 | 0 | 0 | Against |
| Vanguard | 944,022 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 0 | 939,716 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 787,302 | 0 | 0 | 0 | For |
| SEGALL BRYANT & HAMILL, LLC | 726,933 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 600,315 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 585,228 | 0 | 0 | 0 | For |
Institutional-manager reports, all 214 managers: 78,217,749 for, 2,874,121 against, 1,498 not voted, 2,338,592 mixed, 1,500 unknown. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR 2025.
BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“The proposed ratification of the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2025 was approved by the following votes:”): 174,697,892 for, 3,838,292 against — passed, per its Form 8-K filed June 16, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposed ratification of the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2025 was approved by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 21,168,710 | 1,746 | 0 | 0 | For |
| BlackRock | 11,197,803 | 0 | 0 | 0 | For |
| Fidelity | 5,530,927 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 3,546,540 | 0 | 0 | 0 | For |
| TIAA | 3,538,660 | 0 | 0 | 0 | For |
| State Street | 3,243,980 | 158 | 0 | 0 | For |
| Charles Schwab | 1,949,072 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,456,895 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 1,036,408 | 0 | 0 | 0 | For |
| Invesco | 839,792 | 0 | 0 | 0 | For |
| First Trust | 650,165 | 0 | 0 | 0 | For |
| Equitable | 602,022 | 0 | 0 | 0 | For |
| AMG FUNDS | 529,317 | 0 | 0 | 0 | For |
| John Hancock | 464,407 | 0 | 0 | 0 | For |
| Voya | 382,458 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 357,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 356,586 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 353,540 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 309,522 | 0 | 0 | 0 | For |
| Lincoln Financial | 286,448 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 266,386 | 0 | 0 | 0 | For |
| Goldman Sachs | 250,799 | 0 | 0 | 0 | For |
| Federated Hermes | 182,425 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 152,985 | 0 | 0 | 0 | For |
| American Century | 137,097 | 0 | 0 | 0 | For |
Fund voting reports, all 65 managers: 60,434,568 for, 19,093 against, 50,417 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RP Management, LLC | 3,846,154 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 3,846,154 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 209,208,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.12% |
| 2 | BlackRock | 5.35% |
| 3 | Fidelity | 2.64% |
| 4 | ACAP Strategic Fund | 1.70% |
| 5 | TIAA | 1.69% |
| 6 | State Street | 1.55% |
| 7 | Charles Schwab | 0.93% |
| 8 | Columbia Threadneedle | 0.70% |
| 9 | Advantage Advisers Xanthus Fund, L.L.C. | 0.50% |
| 10 | Invesco | 0.40% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 4.53% |
| 2 | Avoro Capital Advisors LLC | 3.62% |
| 3 | State Street | 3.49% |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. | 2.69% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.39% |
| 6 | RP Management, LLC | 1.84% |
| 7 | Nuveen | 1.70% |
| 8 | ALKEON CAPITAL MANAGEMENT LLC | 1.33% |
| 9 | Fisher Asset Management, LLC | 1.29% |
| 10 | GW&K Investment Management, LLC | 1.14% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 22.12% | 13F |
| BlackRock | 17.05% | 13F |
| JPMorgan Chase | 9.44% | 13F |
| T. Rowe Price | 9.18% | 13F |
| FMR (Fidelity) | 8.59% | 13F |
| State Street | 7.78% | 13F |
| RA Capital Management, L.P. | 7.31% | 13G |
| Deerfield Mgmt, L.P. | 6.85% | 13G |
| Avoro Capital Advisors LLC | 6.24% | DEF14A |
| Franklin Templeton | 6.08% | 13F |
Percentages above are of 209,208,000 shares outstanding, as reported by BIOCRYST PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOCRYST PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At BIOCRYST PHARMACEUTICALS INC.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 264 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,300 separate fund positions. On the most widely held item on that ballot — To hold a non-binding, advisory vote regarding executive compensation. — BIOCRYST PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BIOCRYST PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2025.
BIOCRYST PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.